Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice-Reference-Cited by-同舟云学术

Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice

Published:2014-10 Issue:5 Volume:23 Page:573-578
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Bonifazi Martina,Franchi Matteo,Rossi Marta,Zambelli Alberto,Moja Lorenzo,Zambon Antonella,Corrao Giovanni,La Vecchia Carlo,Zocchetti Carlo,Negri Eva

Funder

Programma Integrato 'Come Coniugare Innovazione e Appropriatezza nell'Assistenza al Paziente Oncologico

Fondazione Umberto Veronesi

Italian Association for Cancer Research

Italian Foundation for Cancer Research

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference27 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

2. Amplification of a novel v-erbB-related gene in a human mammary carcinoma;King;Science,1985

3. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

4. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer;Paik;J Clin Oncol,1990

5. Trastuzumab product approval information – licensing action 9/25/98, EMEA EPAR H-C-278. Scientific discussion for the approval of Herceptin;EMEA,2004

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data;European Journal of Cancer;2024-09

2. Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2‐Positive Breast Cancer;International Journal of Breast Cancer;2024-01

3. Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan;Breast Cancer: Targets and Therapy;2023-08

5. Characterization of 940 Chinese patients with triple-positive breast cancer by clinicopathological and treatment outcomes;2022-10-11